MDT and patient perspectives on shared decision making for emerging treatment options

touchMDT for touchONCOLOGY

Listen to key experts from a multidisciplinary team, plus a survivor of metastatic NSCLC, discuss the importance of involving patients in their treatment decisions and how clinicians can best support patients throughout their treatment journey.

The multidisciplinary team:

• Medical Oncologist: Prof. Raffaele Califano, The Christie and Manchester University Hospital, Manchester, UK
• Oncology Pharmacist: Prof. Lisa Holle, University of Connecticut School of Medicine, Storrs, and UConn Health: Neag Comprehensive Cancer Center, Farmington, CT, USA
• Patient Advocate: Mr Josh Colow, Woodstock, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/